<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>23546464</identifier>
<setSpec>1988-9518</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>García-Vázquez, Elisa</dc:author>
<dc:author>Laso-Ortiz, Alicia</dc:author>
<dc:author>Herrero-Martínez, José Antonio</dc:author>
<dc:author>Gómez-Gómez, Joaquín</dc:author>
<dc:author>Hernández-Torres, Alicia</dc:author>
<dc:description xml:lang="en">Despite the relative high frequency of Candida bloodstream infection, Candida endocarditis is a rare entity. We report five cases of Candida endocarditis admitted to our hospital in the period between 2005 and 2011. Two cases were caused by C. albicans, two cases were caused by C. parapsilosis and in the last one, we didn't identify the species of Candida. All but one had clear risk factors for candidemia. Treatment consisted of amphotericin B with / without flucytosine in four patients, and they all underwent surgery for valve replacement and / or removal of intravascular devices. Overall mortality was 60% (40% of mortality was directly related to endocarditis). All patients who survived were given suppressive therapy with fluconazole for a minimum of two years.After stopping fluconazole there was a case of recurrence.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 Mar </dc:date>
<dc:title xml:lang="es">Endocarditis por Candida sp. Experiencia en un hospital terciario y revisión de la literatura.</dc:title>
<dc:title xml:lang="en">[Candida sp endocarditis. Experience in a third-level hospital and review of the literature].</dc:title>
<dc:publisher>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</dc:publisher>
</metadata>
</record>
</pubmed-document>
